BIIB34:BVMF
Biogen Inc BDR
184,49 R$
0,00%
(0,00) 1D
5 қаз., 15:59:13 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
32,39 млрд
Avg. vol.
7,00
Volume
0,00
52-wk high
191,00 R$
52-wk low
128,69 R$
Shares outstanding
147,75 млн
No. of employees
8 мың
Mkt. cap
32,39 млрд
Avg. vol.
7,00
Volume
0,00
52-wk high
191,00 R$
52-wk low
128,69 R$
Shares outstanding
147,75 млн
No. of employees
8 мың
News stories
From web sources and news partners
AD HOC NEWS
·
8 сағат бұрын
Biogen stock heads toward October 28 results after 1.69 percent gain
Pluang
·
12 сағат бұрын
Biogen expected to slightly beat Q3 earnings wi...
Proactive financial news
·
17 сағат бұрын
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Kalkine Media
·
1 күн бұрын
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7,5 мың
Founded1978
HeadquartersКэмбридж, Массачусетс, Америка Құрама Штаттары
Sector-
Websitebiogen.com